Skip to main content

Advertisement

SpringerLink
Log in

Immunogenic Oxidized Low-density Lipoprotein/β2-glycoprotein I Complexes in the Diagnostic Management of Atherosclerosis

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Oxidized low-density lipoprotein (oxLDL) promotes atherosclerosis through a complex interaction of inflammatory and immunologic factors that lead to macrophage lipid uptake and foam cell formation. OxLDL interacts with β2-glycoprotein I (β2GPI) forming oxLDL/β2GPI complexes. These complexes may be formed in the arterial intima during atherogenesis and released into the circulation. Autoantibodies against oxLDL/β2GPI complexes have been demonstrated in patients with systemic lupus erythematosus and/or antiphospholipid syndrome, and shown to be significantly associated with arterial thrombosis. The observation that monoclonal autoantibodies against oxLDL/β2GPI complexes significantly increased the oxLDL uptake by macrophages strongly suggests that such IgG autoantibodies are pro-atherogenic. In this article, we review the recent progress in our understanding of LDL oxidation, oxLDL/β2GPI complex formation, and immune regulation of atherogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G (1997) Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: a meta analysis. Lupus 6:467–473

    Article  PubMed  CAS  Google Scholar 

  2. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ (1992) Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117:997–1002

    PubMed  CAS  Google Scholar 

  3. Hughes GRV, Harris EN, Gharavi AE (1986) The anticardiolipin syndrome. J Rheumatol 13:486–489

    PubMed  CAS  Google Scholar 

  4. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2:1211–1214

    Article  PubMed  CAS  Google Scholar 

  5. Harris EN, Chan JKH, Asherson RA, Hughes GRV (1986) Thrombosis, recurrent fetal loss and thrombocytopenia—predictive value of the anticardiolipin antibody test. Arch Intern Med 146:2153–2156

    Article  PubMed  CAS  Google Scholar 

  6. Shah NM, Khamashta MA, Atsumi T, Hughes GR (1998) Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 7:3–6

    Article  PubMed  CAS  Google Scholar 

  7. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997

    Article  PubMed  CAS  Google Scholar 

  8. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Euro-Phospholipid Project Group et al (2002) Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027

    Article  PubMed  Google Scholar 

  9. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338–436

    Article  PubMed  CAS  Google Scholar 

  10. Aranow C, Ginzler EM (2000) Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 9:166–169

    Article  PubMed  CAS  Google Scholar 

  11. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A et al (2003) Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62:1071–1077

    Article  PubMed  CAS  Google Scholar 

  12. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, Kuller LH (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51–60

    Article  PubMed  CAS  Google Scholar 

  13. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399–2406

    Article  PubMed  CAS  Google Scholar 

  14. Schattner A, Liang MH (2003) The cardiovascular burden of lupus; a complex challenge. Arch Intern Med 163:1507–1510

    Article  PubMed  Google Scholar 

  15. American Heart Association, Heart Disease and Stroke Statistics—2005 Update. http://www.americanheart.org

  16. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126

    Article  PubMed  CAS  Google Scholar 

  17. Virella G, Atchley DH, Koskinen S, Zheng D, Lopes-Virella M (2002) Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 105:81–92

    Article  PubMed  CAS  Google Scholar 

  18. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R et al (1992) Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet 339:883–887

    Article  PubMed  CAS  Google Scholar 

  19. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:2331–2337

    Article  PubMed  CAS  Google Scholar 

  20. Thomas RH (2001) Hypercoagulability syndromes. Arch Intern Med 161:2433–2439

    Article  PubMed  CAS  Google Scholar 

  21. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T (1994) Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen-modified solid phase surface. J Exp Med 179:457–462

    Article  PubMed  CAS  Google Scholar 

  22. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87:4120–4124

    Article  PubMed  CAS  Google Scholar 

  23. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ (2001) β2-glycoprotein I dependent anticardiolipin antibodies and the risk of ischemic stroke and myocardial infarction. Stroke 32:1701–1706

    PubMed  CAS  Google Scholar 

  24. Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA (2004) Anti-β2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 121:142–149

    Article  PubMed  CAS  Google Scholar 

  25. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S et al (1989) Evidence for presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 85:1086–1095

    Article  Google Scholar 

  26. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J et al (1999) Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99:2227–2230

    PubMed  CAS  Google Scholar 

  27. George J, Harats D, Gilburd B, Afek A, Shaish A, Kopolovic J, Shoenfeld Y (2000) Adoptive transfer of B2-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102:1822–1827

    PubMed  CAS  Google Scholar 

  28. Ames PRJ, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J (1999) Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology 38:529–534

    Article  PubMed  CAS  Google Scholar 

  29. Pratico D, Ferro D, Iuliano L, Rokach J, Conti F, Valesini G, Fitzgerald GA, Violi F (1999) Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood 93:3401–3407

    PubMed  CAS  Google Scholar 

  30. Ames PRJ, Tommasino C, Alves J, Morrow JD, Iannaccone L, Fossati G, Caruso S, Caccavo F, Brancaccio V (2000) Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. Lupus 9:688–695

    Article  PubMed  CAS  Google Scholar 

  31. Morgan PE, Sturgess AD, Davies M (2005) Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 52:2869–2879

    Google Scholar 

  32. Frostegard J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L et al (2005) Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52:192–200

    Article  PubMed  CAS  Google Scholar 

  33. Rose N, Afanasyeva M (2003) Autoimmunity: busting the atheorsclerotic plaque. Nat Med 9:641–642

    Article  PubMed  CAS  Google Scholar 

  34. McMurray HF, Parthasarathy S, Steinberg D (1993) Oxidatively modified low-density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest 92:1004–1008

    Article  PubMed  CAS  Google Scholar 

  35. Fong LG, Parthasarathy S, Witztum JL, Steinberg D (1987) Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res 28:1466–1477

    PubMed  CAS  Google Scholar 

  36. Esterbauer H, Jurgens G, Quehenberger O, Koller E (1987) Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 28:495–509

    PubMed  CAS  Google Scholar 

  37. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T et al (1994) A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phsophatidylcholine and polypeptides. J Biol Chem 269:15274–15279

    PubMed  CAS  Google Scholar 

  38. Friedman P, Horkko S, Steinberg D (2001) Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids: importance of Schiff base formation and Aldol condensation. J Biol Chem 277:7010–7020

    Article  PubMed  CAS  Google Scholar 

  39. Anuurad E, Boffa MB, Koschinsky ML, Berglund L (2006) Lipoprotein (a): a unique risk factor for cardiovascular disease. Clin Lab Med 26:751–772

    Article  PubMed  Google Scholar 

  40. Danesh J, Collins R, Petro R (2000) Lipoprotein (a) and coronary heart disease. Meta-analoysis of prospective studies. Circulation 102:1082–1085

    PubMed  CAS  Google Scholar 

  41. Tsimikas S, Witztum JL (2008) The role of oxidized phsopholipids in mediating lipoprotein (a) atherogenicity. Curr Opin Lipid 19:369–377

    Article  CAS  Google Scholar 

  42. Roubey RA (1994) Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 84:2854–2867

    PubMed  CAS  Google Scholar 

  43. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, Van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335:1544–1547

    Article  PubMed  CAS  Google Scholar 

  44. Sheng Y, Kandiah DA, Krilis SA (1998) β2-glycoprotein I: Target antigen for ‘antiphospholipid’ antibodies. Immunological and molecular aspects. Lupus 7:S5–S9

    Article  PubMed  CAS  Google Scholar 

  45. Vaarala O (1996) Antiphospholipid antibodies and atherosclerosis. Lupus 5:442–447

    PubMed  CAS  Google Scholar 

  46. Vaarala O (1998) Antiphospholipid antibodies in myocardial infarction. Lupus 7:S132–s134

    Article  PubMed  CAS  Google Scholar 

  47. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923–925

    Article  PubMed  CAS  Google Scholar 

  48. Steinberg D (1997) Low-density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272:20963–20966

    Article  PubMed  CAS  Google Scholar 

  49. Heinecke JW (1997) Mechanisms of oxidative damage of low-density lipoprotein in human atherosclerosis. Curr Opin Lipid 8:268–274

    Article  CAS  Google Scholar 

  50. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T (1997) Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107:569–573

    Article  PubMed  CAS  Google Scholar 

  51. Kobayashi K, Matsuura E, Liu Q, Furukawa J, Kaihara K, Inagaki J, Atsumi T et al (2001) A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 42:697–709

    PubMed  CAS  Google Scholar 

  52. Liu Q, Kobayashi K, Inagaki J, Sakairi N, Iwado A, Yasuda T, Koike T, Voelker DR, Matsuura E (2002) ω-carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res 43:1486–1495

    Article  PubMed  CAS  Google Scholar 

  53. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y, Khamashta MA, Hughes GRV (2003) Oxidized low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome. Lupus 12:550–554

    Article  PubMed  CAS  Google Scholar 

  54. Kobayashi K, Kishi M, Atsumi T, Bertolaccini ML, Makino H, Sakairi N et al (2003) Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 44:716–726

    Article  PubMed  CAS  Google Scholar 

  55. Maiti SN, Balasubramanian K, Ramoth JA, Shroit AJ (2008) Beta-2 glycoprotein I-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members. J Biol Chem 283:3761–3766

    Article  PubMed  CAS  Google Scholar 

  56. Lopez LR, Hurley BL, Simpson DF, Matsuura E (2005) Oxidized low-density lipoprotein/B2-glycoprotein I complexes in type 2 diabetes mellitus. Ann N Y Acad Sci 1051:97–103

    Article  PubMed  CAS  Google Scholar 

  57. Kasahara J, Kobayashi K, Maeshima Y, Yamasaki Y, Yasuda T, Matsuura E, Makino H (2004) Clinical significance of serum oxidized low-density lipoprotein/B2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Practice 98:15–24

    Article  CAS  Google Scholar 

  58. Matsuura E, Kobayashi K, Inoue K, Lopez LR, Schoenfeld Y (2005) Oxidized LDL/B2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 14:736–741

    Article  PubMed  CAS  Google Scholar 

  59. Lopez LR, Simpson DF, Hurley BL, Matsuura E (2005) OxLDL/β2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann N Y Acad Sci 1051:313–322

    Article  PubMed  CAS  Google Scholar 

  60. Lopez D, Garcia-Valladares I, Palafox-Sanchez C, Garcia De La Torre I, Kobayashi K, Matsuura E, Lopez LR (2004) Oxidized low-density lipoprotein/β2-glycoprotein I complexes and autoantibodies to oxLig-1/β2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol 121:426–436

    Article  PubMed  CAS  Google Scholar 

  61. Lopez D, Kobayashi K, Merrill JT, Matsuura E, Lopez LR (2003) IgG Autoantibodies against β2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol 10:203–211

    Article  PubMed  CAS  Google Scholar 

  62. Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Arienti S, Rampudda ME, Shoenfeld Y, Doria A (2006) OxLDL/β2GPI, anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev (Elsevier), Editors Shoenfeld & Gershwin, Abstracts of the 5th International Congress on Autoimmunity, Sorrento, Italy, pp 19–20

  63. Pengo V, Bison E, Ruffatti A, Iliceto S (2008) Antibodies to oxidized LDL/β2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. Thromb Res doi:10.1016/j.thromres.2007.12.028 (on line)

  64. Matsuura E, Lopez LR (2004) Are oxidized LDL/β2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis? Clin Dev Immunol 11:103–111

    Article  PubMed  CAS  Google Scholar 

  65. Kobayashi K, Lopez LR, Shoenfeld Y, Matsuura E (2005) The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis. Ann N Y Acad Sci 1051:442–454

    Article  PubMed  CAS  Google Scholar 

  66. Lopez LR, Salazar-Paramo M, Palafox-Sanchez C, Hurley BL, Matsuura E, Garcia De La Torre I (2006) Oxidized low-density lipoprotein and B2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 15:80–86

    Article  PubMed  CAS  Google Scholar 

  67. Greco TP, Conti-Kelly AM, Matsuura E, Greco T Jr, Dier KJ, Svanas G, Doyle R, Lopez LR (2007) Antiphospholipid antibodies in patients with coronary artery disease. New cardiac risk factors? Ann N Y Acad Sci 1108:466–474

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Corgenix, Inc., 11575 Main Street, #400, Broomfield, CO, 80020, USA

    Luis R. Lopez

  2. Department of Cell Chemistry, University of Okayama Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558, Japan

    Kazuko Kobayashi, Yukana Matsunami & Eiji Matsuura

Authors
  1. Luis R. Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuko Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yukana Matsunami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eiji Matsuura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis R. Lopez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lopez, L.R., Kobayashi, K., Matsunami, Y. et al. Immunogenic Oxidized Low-density Lipoprotein/β2-glycoprotein I Complexes in the Diagnostic Management of Atherosclerosis. Clinic Rev Allerg Immunol 37, 12–19 (2009). https://doi.org/10.1007/s12016-008-8096-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-008-8096-8

Keywords

Search

Navigation